Charcot-Marie-Tooth Disease
The most common inherited peripheral neuropathy, causing progressive weakness and sensory changes in the feet, legs, hands, and arms.
- Multiple Inheritance Patterns
- Slowly Progressive Course
- Specialist Neuromuscular Review
- Prevalence
- Most common inherited neuropathy (~1 in 2,500)
- Inheritance Pattern
- AD / AR / X-linked (varies by subtype)
- Key Genes
- PMP22, MFN2, GJB1, MPZ
- Care Focus
- Neurology, Orthopedics, Rehabilitation
Condition Overview
Charcot-Marie-Tooth (CMT) disease is the most common inherited disorder affecting the peripheral nerves, the nerves that carry signals between the brain and spinal cord and the muscles and sensory organs. It results from mutations in any of dozens of genes involved in the structure or function of peripheral nerve fibers and their myelin coating.
CMT typically causes slowly progressive weakness and muscle wasting, beginning most often in the feet and lower legs and sometimes extending to the hands and forearms, along with reduced sensation. Severity and rate of progression vary considerably depending on the specific genetic subtype.
While CMT is not life-threatening for most patients, it can significantly affect mobility and quality of life over time, making accurate genetic diagnosis and coordinated neuromuscular and orthopedic care important.
Types and Subtypes
CMT is broadly classified by the underlying nerve pathology and inheritance pattern, with more than 80 implicated genes identified to date.
Symptoms and Signs
CMT typically presents with a slowly progressive combination of motor and sensory symptoms, usually starting distally in the feet and hands.
Causes and Risk Factors
CMT is caused by inherited mutations in genes affecting the structure or function of peripheral nerves, with more than 80 genes identified across different subtypes.
Diagnosis and Investigations
Diagnosis combines clinical examination, electrophysiological testing, and genetic confirmation.
Disease Course and Severity Classification
CMT does not follow a tumor-style staging system. Clinicians instead classify severity based on functional impact and rate of progression to guide management.
Standard Treatment Approach
There is currently no cure for CMT; management is supportive and focused on maintaining mobility, function, and independence.
Advanced and Emerging Treatment Options
Active research is exploring disease-modifying approaches for specific CMT subtypes, though none are yet broadly approved.
Gene Therapy
Subtype-Specific Gene Therapy Research
Early-stage gene therapy and gene-silencing approaches are being studied for specific CMT subtypes, such as PMP22-related CMT1A.
Pharmacologic Research
PMP22 Expression Modulators
Compounds aimed at normalizing PMP22 gene expression are under clinical investigation for CMT1A.
Precision Medicine
Genotype-Guided Management
Increasingly, management and trial eligibility are being tailored to the specific genetic subtype identified.
Genetic Markers and Precision Diagnosis
Identifying the specific causative gene and pathology type supports tailored prognosis discussions and clinical trial eligibility.
When a Second Opinion May Be Important
Given the genetic heterogeneity of CMT, specialist neuromuscular input can clarify diagnosis and management.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Most people with CMT have a normal life expectancy, though the degree of disability varies considerably depending on the genetic subtype and individual disease course.
Supportive Care and Living with Charcot-Marie-Tooth Disease
Because CMT is a lifelong, slowly progressive condition, supportive care plays a central role in maintaining independence and quality of life.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with a Charcot-Marie-Tooth disease diagnosis access specialist neuromuscular second opinions, clarify genetic subtype, and learn about emerging gene-targeted research opportunities.
Get a free case reviewFrequently Asked Questions
Charcot-Marie-Tooth disease is the most common inherited disorder of the peripheral nerves, causing progressive weakness and sensory loss, most often beginning in the feet and lower legs.
Early signs often include foot drop, frequent tripping, high-arched feet, and hammertoes, sometimes first noticed in childhood or adolescence.
Yes, it is caused by inherited mutations in any of more than 80 genes, with inheritance patterns that can be autosomal dominant, autosomal recessive, or X-linked depending on the subtype.
Diagnosis typically involves a neurological exam, nerve conduction studies, and genetic testing to identify the specific causative gene mutation.
There is currently no cure. Management focuses on physical therapy, orthotic support, and monitoring, while gene therapy and gene-silencing approaches are being studied in research settings for some subtypes.
Most people with CMT have a normal life expectancy; the condition primarily affects mobility and hand function rather than overall survival.
Yes, CMT is typically slowly progressive over years to decades, though the rate and degree of progression vary widely depending on the genetic subtype.
Care typically involves neurology, physical and occupational therapy, orthopedics, and genetic counseling.
Yes, CMT often first becomes apparent in childhood or adolescence, though severity and age of onset vary by genetic subtype.
Yes. CancerFax can help coordinate review of nerve conduction and genetic test results, connect patients with specialist neuromuscular second opinions, and share information on emerging gene-targeted research, including cross-border coordination where appropriate.
Have a Charcot-Marie-Tooth Disease Diagnosis?
Get expert review of nerve conduction and genetic test results to support confident care planning.